Liposomal doxorubicin (TLC D-99), cyclophosphamide, oncovin and prednisone (COP) in the treatment of aggressive non-Hodgkin's lymphomas (NHL).

被引：0
|
作者：
Levine, AM
Tulpule, A
Espina, BM
Buchanan, LH
Africano, M
Boswell, W
Welles, L
机构：
[1] Univ So Calif, Keck Med Sch, Los Angeles, CA USA
[2] Liposome Co, Princeton, NJ USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
587
引用
收藏
页码：137A / 137A
页数：1
相关论文
共 50 条
  • [1] Liposomal doxorubicin (TLC D99, myocet) in combination with cyclophosphamide (C), vincristine (O) and prednisone (P) for aggressive non-Hodgkin's lymphomas (NHL).
    Levine, A
    Tulpule, A
    Espina, B
    Buchanan, L
    Africano, M
    Welles, L
    ANNALS OF ONCOLOGY, 2000, 11 : 105 - 106
  • [2] Liposomal doxorubicin (TLC-D99) in combination with cyclophosphamide (C), vincristine (V), and prednisone (P) is active in newly diagnosed aggressive non-Hodgkin's lymphoma (NHL).
    Tulpule, A
    Espina, BM
    Berman, N
    Buchanan, LH
    Boswell, WD
    Welles, L
    Levine, AM
    BLOOD, 2001, 98 (11) : 346A - 346A
  • [3] Efficacy of cyclophosphamide, doxorubicin, etoposide and prednisone (CHEP) chemotherapy in previously untreated aggressive non-Hodgkin's lymphoma (NHL).
    Lee, WS
    Joo, YD
    Chung, JS
    Cho, GJ
    Park, KT
    Sohn, CH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 614S - 614S
  • [4] Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide,vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma
    Tulpule, Anil
    Espina, Byron M.
    Berman, Nancy
    Buchanan, Laura H.
    Smith, D. Lynne
    Sherrod, Andy
    Dharmapala, Dharshika
    Gee, Conway
    Boswell, William D.
    Nathwani, Bharat N.
    Welles, Lauri
    Levine, Alexandra M.
    CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (01) : 59 - 64
  • [5] Treatment of relapsed non-Hodgkin's-lymphoma (NHL) with liposomal Daunoxome® in combination with cyclophosphamide, vincristine and prednisone (CDaXOP).
    Röhnisch, T
    Zippelius, A
    Vehling-Kaiser, U
    Hiller, E
    Dreyling, M
    Jung, C
    Oduncu, F
    Emmerich, B
    Hiddemann, W
    Hallek, M
    BLOOD, 1999, 94 (10) : 525A - 525A
  • [6] A phase II trial of pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin's lymphoma
    Tulpule, A
    Khan, AU
    Mohrbacher, AF
    Espina, BM
    Buchanan, L
    Berman, N
    Gorospe, G
    Boswell, WD
    Nathwani, BN
    Levine, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 604S - 604S
  • [7] Treatment of aggressive non-Hodgkin's lymphomas
    Kaiser, U
    Trumper, L
    Pfreundschuh, M
    Havemann, K
    INTERNIST, 1997, 38 (02): : 135 - 142
  • [8] Treatment of aggressive non-Hodgkin's lymphomas
    Moreno Nogueira, J. A.
    Ruiz Borrego, M.
    Perez Valderrama, B.
    Valero Azbiru, M.
    REVISTA CLINICA ESPANOLA, 2009, 209 (02): : 88 - 92
  • [9] Treatment of aggressive Non-Hodgkin's-Lymphomas (NHL) with Bendamustine: The Jena experience
    Hammersen, J.
    Sommer, M.
    Goessel, C.
    Teichgraeber, U.
    Hahnfeld, S.
    Scholl, S.
    Fricke, H. -J
    Wedding, U.
    Eigendorff, E.
    Petersen, I
    Merz, H.
    Hochhaus, A.
    La Rosee, P.
    ONKOLOGIE, 2013, 36 : 137 - 137
  • [10] A phase II trial of pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone (DR-COP) in aggressive B-cell non-Hodgkin's lymphoma.
    Tulpule, A
    Duran, CA
    Smith, DL
    Berman, NE
    Buchanan, L
    Gorospe, G
    Boswell, W
    Nathwani, B
    Levine, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 593S - 593S
12345